Posts

The Memo: Marine Biomedical Turning Mother of Pearl Into the Next Generation of Bone Grafts

Under the direction of CEO Rolee Kumar, Marine Biomedical is advancing a novel approach to bone regeneration by transforming mother of pearl from Western Australia’s pearling industry into a biomaterial designed to support natural bone healing. Built on research originating at the University of Western Australia, the company has developed PearlBone™, a marine-derived bone graft substitute that combines the consistency and scalability of manufactured materials with the biological architecture found in nature. With an FDA 510(k) submission under review, a planned clinical trial on the horizon, and manufacturing operations established in Broome, Marine Biomedical is working to bring an entirely new category of regenerative biomaterials to orthopedic surgeons. Origin Story Marine Biomedical’s roots can be traced back to the University of Western Australia and the work of regenerative medicine pioneer Professor Ming Hao Zheng, who recently received the Member of the Order of Australia for h...
Post a Comment
Read more

The Memo: Earflo Giving Families an Option Before Surgery

Under the direction of Co-Founder and CEO Intan Oldakowska, PhD, Earflo has brought to market an FDA-cleared, at-home medical device designed to treat the negative middle ear pressure that leads to fluid buildup and chronic ear infections and avoid the path toward surgery. By transforming treatment into something as familiar as drinking from a sippy cup, Earflo aims to address one of the most common pediatric conditions with a solution that is non-invasive, child-friendly, and designed for use at home. Following FDA clearance and a U.S. commercial launch, the company is now focused on expanding access for families while building evidence that earlier intervention can improve quality of life for both children and parents and help avoid ear tube surgery. Origin Story Earflo traces its roots to the Stanford Biodesign program, where innovators are trained to identify significant unmet clinical needs before ever thinking about solutions. For Oldakowska and her future co-founders, that proce...
Post a Comment
Read more

The Memo: Flux Robotics Brings Magnetic Precision to Vascular Navigation

Under the direction of Founder and CEO Christoff Heunis, PhD, Flux Robotics is developing a magnetic vascular navigation platform designed to give physicians more controlled steering of guidewire movement inside blood vessels. By replacing the traditional reliance on pushing and twisting wires from outside the body with magnetically guided tip steering, the company aims to make one of the most challenging steps in vascular intervention more predictable, repeatable, and accessible. As vascular disease burdens rise worldwide and specialist shortages intensify, Flux is pursuing a new approach to minimally invasive surgery that could help more physicians successfully treat more patients. Origin Story For Heunis, the inspiration behind Flux Robotics traces back to a deeply personal experience. “When I was 20, studying mechatronic engineering in South Africa, my best friend Shaun called me,” he recalled. “I’ve known Shaun since I was five, and his mother was like family to me. She had suffer...
Post a Comment
Read more

The Memo: EndoShunt Medical Giving Surgeons the Gift of Time So They Can Give Patients the Gift of Life

Under the direction of CEO Tyler Zanon, EndoShunt Medical is developing a minimally invasive endovascular shunting device designed to give trauma surgeons temporary, targeted control over abdominal blood flow while maintaining perfusion to the rest of the body. In the most severe hemorrhage cases, where every minute can shape both survival and long-term quality of life, EndoShunt is working to replace blunt tools with a more controlled approach. As Zanon put it, “EndoShunt gives trauma surgeons the gift of time, so they can give trauma patients the gift of life.” Origin Story For Zanon, the mission behind EndoShunt is closely tied to the realities of trauma care. Based in Chicago, he has spent roughly 15 years in healthcare product development, first in academia and then in industry. Living in a major city with high rates of traumatic injury, he has seen how urgent the problem remains. “We haven’t seen actual innovation since World War II,” Zanon said. He often explains the challenge w...
Post a Comment
Read more

Medtech M&A Activity Is Rising, But Is It Really a Boom?

Over the past several weeks, acquisition announcements have arrived at a rapid pace across the industry. Between transactions involving Medtronic, ResMed, Artivion, and Roche, nearly $2 billion in deal value has been announced in a short period of time. The headlines naturally raise a question: are we witnessing a true surge in medtech M&A , or are a handful of high-profile deals creating that impression? A review of recent transactions, combined with activity tracked in Compass AI , suggests that strategic buyers remain highly active. However, the broader data indicate a market that is accelerating within an established trend rather than entering entirely new territory. The Same Acquisition Playbook Continues to Win Although the companies and technologies differ, the latest transactions share several common characteristics. Strategic acquirers continue to target businesses with commercial traction, attractive growth profiles, and technologies that strengthen existing franchises. R...
Post a Comment
Read more

Neuroimaging and Siemens Healthineers’ Push to Build a Neuro Platform

Siemens Healthineers sits among the largest companies in medtech. With approximately $25 billion in revenue in 2025, the company operates at a scale comparable to some of the industry’s biggest names and continues to invest heavily in markets where it sees long-term growth potential. A series of partnership announcements over the past year offers a window into where Siemens Healthineers appears to be investing for the future. Across robotics, AI, diagnostics software, and health system infrastructure, Siemens Healthineers has assembled a network of relationships that increasingly points toward one destination: neuro. Viewed individually, each agreement serves a specific purpose. Taken together, they suggest a broader strategy centered on neuroimaging, precision therapy, and integrated clinical workflows. A Company Becoming More Focused Siemens AG announced plans to deconsolidate its majority stake in Siemens Healthineers, a process that has been underway for some time. For Healthineers...
Post a Comment
Read more

Medtech Q1 Earnings: What the Major Strategics Are Telling Us

With Q2 already underway, the latest medtech Q1 earnings reports offer an early read on where major strategics are gaining momentum, where pressure is building, and what strategic priorities are becoming clearer. This quarter’s results point to a consistent theme: focused portfolios are outperforming broader platforms. Companies concentrated in clearly defined growth markets, particularly cardiovascular/structural heart, are delivering stronger execution. More diversified players remain highly competitive, but they are managing a wider mix of operational, integration, and macroeconomic challenges. A closer look at the numbers makes that trend difficult to ignore. Focused Players Continue to Separate Themselves Abbott delivered $5.5 billion in Q1 Medical Devices revenue, representing 8.5% organic growth and 13.2% reported growth year over year. Electrophysiology, Rhythm Management, and Heart Failure each posted double-digit gains, while the U.S. launch of Volt supported EP performance. ...
Post a Comment
Read more